Your browser doesn't support javascript.
loading
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
Johnson, Erik C B; Bian, Shijia; Haque, Rafi U; Carter, E Kathleen; Watson, Caroline M; Gordon, Brian A; Ping, Lingyan; Duong, Duc M; Epstein, Michael P; McDade, Eric; Barthélemy, Nicolas R; Karch, Celeste M; Xiong, Chengjie; Cruchaga, Carlos; Perrin, Richard J; Wingo, Aliza P; Wingo, Thomas S; Chhatwal, Jasmeer P; Day, Gregory S; Noble, James M; Berman, Sarah B; Martins, Ralph; Graff-Radford, Neill R; Schofield, Peter R; Ikeuchi, Takeshi; Mori, Hiroshi; Levin, Johannes; Farlow, Martin; Lah, James J; Haass, Christian; Jucker, Mathias; Morris, John C; Benzinger, Tammie L S; Roberts, Blaine R; Bateman, Randall J; Fagan, Anne M; Seyfried, Nicholas T; Levey, Allan I.
Afiliação
  • Johnson ECB; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA. erik.johnson@emory.edu.
  • Bian S; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. erik.johnson@emory.edu.
  • Haque RU; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Carter EK; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Watson CM; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Gordon BA; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Ping L; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Duong DM; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Epstein MP; Mallinckrodt Institute of Radiology, Washington University in St Louis, St Louis, MO, USA.
  • McDade E; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Barthélemy NR; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Karch CM; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Xiong C; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Cruchaga C; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • Perrin RJ; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
  • Wingo AP; Department of Neurology, Washington University in St Louis, St Louis, MO, USA.
  • Wingo TS; Department of Neurology, Washington University in St Louis, St Louis, MO, USA.
  • Chhatwal JP; Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.
  • Day GS; Department of Neurology, Washington University in St Louis, St Louis, MO, USA.
  • Noble JM; Division of Biostatistics, Washington University in St Louis, St Louis, MO, USA.
  • Berman SB; Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.
  • Martins R; Department of Neurology, Washington University in St Louis, St Louis, MO, USA.
  • Graff-Radford NR; Department of Pathology and Immunology, Washington University in St Louis, St Louis, MO, USA.
  • Schofield PR; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Ikeuchi T; Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA.
  • Mori H; Division of Mental Health, Atlanta VA Medical Center, Atlanta, GA, USA.
  • Levin J; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Farlow M; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Lah JJ; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
  • Haass C; Massachusetts General and Brigham & Women's Hospitals, Harvard Medical School, Boston, MA, USA.
  • Jucker M; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Morris JC; Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and GH Sergievsky Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Benzinger TLS; Departments of Neurology and Clinical and Translational Science, Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
  • Roberts BR; Edith Cowan University, Perth, Western Australia, Australia.
  • Bateman RJ; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Fagan AM; Neuroscience Research Australia, Sydney, New South Wales, Australia.
  • Seyfried NT; School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
  • Levey AI; Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Nat Med ; 29(8): 1979-1988, 2023 08.
Article em En | MEDLINE | ID: mdl-37550416
ABSTRACT
Alzheimer's disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes-aggregation of the amyloid-ß (Aß) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)-are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aß plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aß plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aß and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aß and tau.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Doença de Alzheimer Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Doença de Alzheimer Idioma: En Ano de publicação: 2023 Tipo de documento: Article